Amikacin liposome inhalation suspension in newly diagnosed Mycobacterium avium complex lung disease (ARISE): a 6-month double-blind, active comparator trial - PubMed
6 hours ago
- #Amikacin liposome inhalation suspension
- #Clinical trial
- #Mycobacterium avium complex
- ALIS (amikacin liposome inhalation suspension) is tested in newly diagnosed MACLD patients.
- The ARISE trial is a 6-month double-blind study comparing ALIS plus azithromycin and ethambutol to an empty liposome control plus the same antibiotics.
- Culture conversion rates were higher with ALIS: 80.6% by month 6 vs. 63.9% with comparator.
- Most ALIS patients achieving conversion had their first negative culture by month 1.
- Quality of Life-Bronchiectasis Respiratory Domain scores improved with ALIS, while the comparator plateaued after month 3.
- Fatigue scores improved in both groups without significant difference between arms.
- No serious adverse events or deaths related to ALIS were reported.
- The study confirms ALIS efficacy in culture conversion and shows no new safety concerns.